Last R$18.97 BRL
Change Today -0.09 / -0.47%
Volume 3.4M
HYPE3 On Other Exchanges
Symbol
Exchange
Sao Paulo
Stuttgart
As of 4:09 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

hypermarcas sa (HYPE3) Snapshot

Open
R$19.16
Previous Close
R$19.06
Day High
R$19.22
Day Low
R$18.97
52 Week High
10/15/13 - R$20.22
52 Week Low
03/5/14 - R$14.22
Market Cap
12.0B
Average Volume 10 Days
2.7M
EPS TTM
R$0.40
Shares Outstanding
632.1M
EX-Date
05/2/13
P/E TM
48.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for HYPERMARCAS SA (HYPE3)

Related News

No related news articles were found.

hypermarcas sa (HYPE3) Related Businessweek News

No Related Businessweek News Found

hypermarcas sa (HYPE3) Details

Hypermarcas S.A., a consumer goods company, is engaged in the development, production, and sale of drug, health, beauty, and personal care products in Brazil. It operates in two segments, Pharmaceutical and Consumer. The company offers sweeteners under the Adocyl, Finn, and Zero-Cal names; and beauty and personal care products, including bleach and hydrogen peroxide, body deodorants, colognes, coloring, deodorants, hair line, hair styling, nail polish, shaving products, skin care, soap, tanner/sunscreen, and transformation products. It also provides child care and health products, such as absorbents, accessories, antiseptics, baby bottles, baby lines, baby powder, toothbrushes and dental products, cloths, condoms, baby diapers, dental creams and gels, dental floss and tapes, diaper rash cream, disposable pads, disposable underwear, feminine hygiene products, diapers, intimate hygiene products, kids lines, lubricants, moistened towels, oral antiseptics, oral supplements, palinets, wet wipes, and cottons. In addition, the company offers pharmaceutical products, including over-the-counter medications, such as laxative, antacid, antispasmodic, topical antiseptic, topical, nasal decongestant drugs, and other products; prescription medications under the Farmasa, Neo Química, and Luper names; generic medications; and dermocosmetics. Hypermarcas S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

12,569 Employees
Last Reported Date: 02/22/14
Founded in 2001

hypermarcas sa (HYPE3) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hypermarcas sa (HYPE3) Key Developments

Hypermarcas S.A. Presents at 7th Annual Citi Brazil Equity Conference, Jun-04-2014

Hypermarcas S.A. Presents at 7th Annual Citi Brazil Equity Conference, Jun-04-2014 . Venue: Intercontinental Hotel Sao Paulo, Alameda Santos 1123, Sao Paulo ­ SP, 01419-001, Brazil.

Hypermarcas S.A. Presents at Citi 2014 Global Consumer Conference, May-28-2014 through May-29-2014

Hypermarcas S.A. Presents at Citi 2014 Global Consumer Conference, May-28-2014 through May-29-2014. Venue: Hilton New York, 1335 6th Ave, New York, NY 10019, United States. Presentation Date(s): May-28-2014. May-29-2014.

Hypermarcas S.A. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Announces Impairment for the First Quarter of 2014

Hypermarcas S.A. announced consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of BRL 1,058,875,000 compared to BRL 958,432,000 for the same period a year ago. Operating income before equity income and financial result was BRL 218,656,000 compared to BRL 190,756,000 for the same period a year ago. Profit before income tax and social contribution was BRL 110,753,000 compared to BRL 137,524,000 for the same period a year ago. Net profit from continued operations was BRL 92,424,000 compared to BRL 102,110,000 for the same period a year ago. Net profit was BRL 90,237,000 compared to BRL 102,310,000 for the same period a year ago. Earnings per share was BRL 0.14645 compared to BRL 0.16305 for the same period a year ago. Net cash provided by operating activities was BRL 170,971,000 compared to BRL 184,323,000 for the same period a year ago. Acquisitions of property, plant and equipment was BRL 55,060,000 compared to BRL 34,212,000 for the same period a year ago. Investment in intangible assets was BRL 5,312,000 compared to BRL 5,000,000 for the same period a year ago. Adjusted EBITDA was BRL 259.0 million compared to BRL 227.1 million for the same period a year ago. EBITDA was BRL 245.0 million compared to BRL 216.3 million for the same period a year ago. Net debt as at March 31, 2014 was BRL 2,836.6 million. For the first quarter 2014, the company reported impairment of BRL 1,460,000 compared to nil for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HYPE3:BZ R$18.97 BRL -0.09

HYPE3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,470 GBp -12.00
Johnson & Johnson $102.20 USD +0.01
Pfizer Ltd/India 1,413 INR -1.00
Sanofi €77.32 EUR +0.39
View Industry Companies
 

Industry Analysis

HYPE3

Industry Average

Valuation HYPE3 Industry Range
Price/Earnings 51.3x
Price/Sales 2.8x
Price/Book 1.7x
Price/Cash Flow 50.9x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERMARCAS SA, please visit www.hypermarcas.com.br. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.